利拉鲁肽联合盐酸吡格列酮片治疗初诊肥胖T2DM患者的效果及对β细胞功能的影响  

The Effect of Liraglutide Combined with Pioglitazone Hydrochloride Tablets in the Treatment of Newly Diagnosed Obese Patients with T2DM and Its Influence on β-cell Function

作　　者：朱锋 ZHU Feng(Putian First Hospital,Putian,Fujian Province,351100 China)

机构地区：[1]莆田市第一医院,福建莆田351100

出　　处：《糖尿病新世界》2021年第19期99-102,共4页Diabetes New World Magazine

摘　　要：目的研究初诊肥胖2型糖尿病患者应用利拉鲁肽联合盐酸吡格列酮治疗方式的临床效果,并探讨其治疗对患者β细胞功能的影响。方法研究时间为2018年1月—2021年1月,随机抽取于该院进行诊治的58例初诊肥胖2型糖尿病患者,按照单盲分组方式进行组别划分,名称为对照组与研究组,每组例数均为29例,对照组应用盐酸吡格列酮,研究组应用盐酸吡格列酮联合注射利拉鲁肽,观察并对比两组患者临床治疗效果。结果研究组患者并发症发生率为3.4%,其数据显著低于对照组,差异有统计学意义(χ^(2)=4.735,P=0.030);研究组患者在空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数、胰岛β细胞功能指数以及体质量方面的数据,分别为(7.03±0.71)mmol/L、(8.24±1.18)mmol/L、(6.41±0.39)%、(1.32±0.35)、(50.14±5.88)、(70.52±3.72)kg,各项指标均明显优于对照组,差异有统计学意义(t=2.057、2.547、10.671、5.651、10.037、2.879,P<0.05)。结论初诊肥胖2型糖尿病患者应用利拉鲁肽注射液联合盐酸吡格列酮片进行治疗,能够降低患者血糖水平与并发症发生率,改善胰岛β细胞功能与胰岛素抵抗指数,临床应用价值显著。Objective To study the clinical effects of liraglutide combined with pioglitazone hydrochloride treatment in newly diagnosed obese type 2 diabetic patients,and to explore the effect of the treatment on β-cell function in patients.Methods A total of 58 newly diagnosed obese type 2 diabetic patients who were diagnosed and treated in the hospital from January 2018 to January 2021 were randomly selected.According to the single-blind grouping method,the groups are divided into the control group and the study group.The number of cases in each group was 29 cases.The control group was treated with pioglitazone hydrochloride,and the study group was treated with pioglitazone hydrochloride combined with liraglutide to observe and compare the clinical treatment effects of the two groups.Results The complication rate in study group was 3.4%,which was significantly lower than that in control group,the difference was statistically significant(χ^(2)=4.735,P=0.030).Fasting blood glucose,2 h postprandial blood glucose,HbA1 c,insulin resistance index,islet beta cell function index and body weight of patients in the study group,(7.03 ±0.71)mmol/L,(8.24 ±1.18)mmol/L,(6.41 ±0.39)%,(1.32 ±0.35),(50.14±5.88),(70.52±3.72)kg,respectively,were significantly better than the control group,the difference was statistically significant(t=2.057,2.547,10.671,5.651,10.037,2.879,P<0.05).Conclusion The treatment of newly diagnosed obese type 2 diabetic patients with liraglutide injection combined with pioglitazone hydrochloride tablets can reduce the blood glucose level and the incidence of complications,improve the function of pancreatic β-cells and insulin resistance index,and has significant clinical application value.

关 键 词：利拉鲁肽 盐酸吡格列酮 肥胖 2型糖尿病 Β细胞功能 

分 类 号：R59[医药卫生—内科学]